Plasma Interleukin 6 Predicts Response to Serotonin Noradrenaline Reuptake Inhibitors in Major Depressive Disorder

We investigated the association between the plasma interleukin-6 (IL-6) level and response to Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Major Depressive Disorder (MDD) patients. Patients with MDD diagnosed by DSM-IV-TR (M/F: 45/52, mean age 48 years) were enrolled in the present study. All participants were treated by monotherapy of duloxetine (n=48) or milnacipran (n=49). The end-point of the present study was week 8. Patients whose HAMD17 scores decreased 50% or more were defined as responders; others were considered nonresponders. Blood was drawn at baseline and 8 weeks after the treatment. Plasma levels of IL-6 were measured. Plasma IL6 at week 0 was higher in the responder group than in the nonresponders group. Plasma IL6 level in the responder group significantly decreased 8 weeks after treatment with antidepressant. These results suggest that plasma IL-6 is related to the response to SNRIs in MDD patients.


Reiji Yoshimura

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • 12th World Congress on Biomarkers & Clinical Research
    October 03-04, California, USA
  • 22nd World Conference on Liquid Biopsy & Biomarkers
    October 15-16, Toronto, Canada
  • International Conference And Expo On Biomarkers and Genomic Medicine 2018
    October 29-30, Osaka, Japan
Flyer image

Abstracted/Indexed in

  • Index Copernicus
  • Google Scholar
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research